OSA is a known independent risk factor for T2DM
and patients with OSA are known to have coexisting risk factors for metabolic syndrome such as obesity.
Thirty-two patients with T2DM
from Sweden were included in this randomised, controlled trial.
A case study suggested the positive impact of social support on a patient with T2DM
(Yarwood-Ross & Randall, 2013).
Moreover, one of the hallmarks of T2DM
is low-grade inflammation, which can result from a rise in circulating cytokines.
We also evaluated the association between chronic periodontitis and glycaemic status, microvascular, and macrovascular complications among individuals having T2DM
with and without chronic periodontitis.
Defects in apoptotic regulatory machinery are implicated in a variety of pathological status: Excess apoptosis is the underlying cause for [beta]-cell loss for both T1DM and T2DM
and inadequate apoptosis may contribute to oncogenesis of pancreatic endocrine tumors (PETs) .
The whole panel stressed that the big problem in the management of T2DM
is that patients usually have no symptoms for a good number of years, and many remain undiagnosed; or if diagnosed, they do not take their prescribed medicines because anyway, they don't have any symptom.
This qualitative study was conducted at the endocrinology and metabolism polyclinic of Akdeniz University, Antalya, Turkey, in 2015, and comprised T2DM
At times, the combination of both can result in T2DM
STENO-2 was an open, parallel-group study initiated in 1993 to compare conventional multifactorial treatment of T2DM
with an intensified approach over an 8-year period.
The ongoing, fully enrolled CREDENCE trial, the first dedicated SGLT2 inhibitor Phase 3 renal outcomes trial, is evaluating the effects of canagliflozin on renal outcomes in patients with T2DM
and kidney disease.
patients have impaired QOL, and a high incidence of depression.